Erythropoietin therapy for early diabetic retinopathy through its protective effects on retinal pericytes

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 266-268

  Wang, Zhao Yang ^a   Zhao, Ke Ke ^b   Zhao, Pei Quan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Children's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; DIABETIC RETINOPATHY; DRUG CLEARANCE; HUMAN; KIDNEY CARCINOMA; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PERICYTE; RETINA;

ANIMALS; ANOXIA; APOPTOSIS; DIABETIC RETINOPATHY; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MICE; MODELS, THEORETICAL; NEURONS; PERICYTES; RETINA; TREATMENT OUTCOME;

EID: 78651092070     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.10.017     Document Type: Article

References (28)

1. Kaur C., Foulds W.S., Ling E.A. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008, 27(6):622-647.
2. Ejaz S., Chekarova I., Ejaz A., et al. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 2008, 10(1):53-63.
3. Hackett S.F., Wiegand S., Yancopoulos G., Campochiaro P.A. Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol 2002, 192:182-187.
4. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996, 97:2883-2890.
5. Frank R.N. Diabetic retinopathy. N Engl J Med 2004, 350(1):48-58.
6. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003, 228(1):1-14.
7. Hardee M.E., Arcasoy M.O., Blackwell K.L., Kirkpatrick J.P., Dewhirst M.W. Erythropoietin biology in cancer. Clin Cancer Res 2006, 12(2):332-339.
8. Bartesaghi S., Marinovich M., Corsini E., Galli C.L., Viviani B. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005, 26(5):923-928.
9. Katavetin P., Tungsanga K., Eiam-Ong S., Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl 2007, 107:S10-S15.
10. Marti H.H. Erythropoietin and the hypoxic brain. J Exp Biol 2004, 207(18):3233-3242.
11. Feng Q. Beyond erythropoiesis: the anti-inflammatory effects of erythropoietin. Cardiovasc Res 2006, 71(4):615-617.
12. Wang Z.Y., Shen L.J., Tu L., et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 2009, 46(8):1032-1041.
13. Wang Z.Y., Zhao K.K., Song Z.M., et al. Erythropoietin as a novel therapeutic agent for atrophic age-related macular degeneration. Med Hypotheses 2009, 72:448-450.
14. Li J., Vesey D.A., Johnson D.W., Gobe G. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 2007, 6(12):1944-1950.
15. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001, 412:641-647.
16. Zhang J., Wu Y., Jin Y., et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008, 49(2):732-742.
17. Zhang J., Hu L.M., Xu G., et al. Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy. Front Biosci (Elite Ed) 2010, 2:912-927.
18. Martinez-Estrada O.M., Rodriguez-Millan E., Gonzalez-De Vicente E., et al. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003, 18:2538-2544.
19. Grimm C., Wenzel A., Groszer M., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002, 8(7):718-724.
20. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000, 97(19):10526-10531.
21. Zhang J.F., Wu Y.L., Xu J.Y. Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. Acta Pharmacol Sin 2008, 29(11):1383-1390.
22. Lagrèze W.A., Feltgen N., Bach M., et al. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 2009, 93:1667-1671.
23. Li W., Sinclair S.H., Xu G.T. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging 2010, 41(1):18-25.
24. Hernandez C., Fonollosa A., Garcia-Ramirez M., et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2006, 29:2028-2033.
25. Chen J., Connor K.M., Aderman C.M., et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118:526-533.
26. Watanabe D., Suzuma K., Matsui S. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005, 353:782-789.
27. Chen J., Connor K.M., Aderman C.M., et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009, 50(3):1329-1335.
28. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305(5681):239-242.